{"name":"Zhi-Hong Liu, M.D.","slug":"zhi-hong-liu-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Emodin","genericName":"Emodin","slug":"emodin","indication":"Other","status":"discontinued"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"tripterygium wilfordii","genericName":"tripterygium wilfordii","slug":"tripterygium-wilfordii","indication":"Rheumatoid arthritis","status":"marketed"}]}],"pipeline":[{"name":"Emodin","genericName":"Emodin","slug":"emodin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"tripterygium wilfordii","genericName":"tripterygium wilfordii","slug":"tripterygium-wilfordii","phase":"marketed","mechanism":"Tripterygium wilfordii extract suppresses immune cell activation and reduces inflammatory cytokine production through multiple pathways including NF-κB inhibition.","indications":["Rheumatoid arthritis","Systemic lupus erythematosus","Other autoimmune and inflammatory disorders"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNZDVxT21vWnlSdl9Oc2pWczNXeEVibkFTZTl1aVZJSzFSUjlJNjVxOU5jZ0s2S3Qzd1J2VE1FNFZ0QmtSck5RNFJTRndKejdkMll0ZWJXVEt3VkxLTFNWekZIRkxQSy1wS3Fibnk1d1dSaTR1VVlLclJQYlozRi1JMDFTWTdGdktmbXkzMVpaQjBPR2RNR09zNDFPaGVKNDFaN1IxWTVNOFk1UDYxOVV2Ti1ENlIzSWoxdWVYQQ?oc=5","date":"2022-02-22","type":"pipeline","source":"Healio","summary":"Obesity may increase diabetic kidney disease risk, especially in women - Healio","headline":"Obesity may increase diabetic kidney disease risk, especially in women","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1QcUlsNWFNcG1seDdfV3c5S2VUUjY2TTVJdjdrTjg5eHZId0NQc0MtTWZPVkIwTFFTWlhoMUM1Qlh6cXVRcTNObnNrMDJaZDAtOUlPLV9ZWGRyR3BJdE84c01wem5XLVRYZkE?oc=5","date":"2021-12-14","type":"pipeline","source":"Wiley Online Library","summary":"Editorial: the three tenors in HBV—TDF, TAF and now TMF. Authors' reply - Wiley Online Library","headline":"Editorial: the three tenors in HBV—TDF, TAF and now TMF. Authors' reply","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1pRmZPTjlXcWthUWRpWFVWVUhMWC0xMHJnbHYxSmRsMk1mQlA5eDZVRXVrNTdobkE5Q3FHRUxFUXRobHlXck1NZFhiNkxNVjhHUVhBMmlpWkFwUVJFaWR4YXhDbGJOVGg5RkE?oc=5","date":"2021-09-29","type":"trial","source":"Wiley Online Library","summary":"Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B - Wiley Online Library","headline":"Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for p","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1jZ1lURGRhZ0NrWVR4VjVYVHExUjRGUnJNRGFzZzh3T095SkJFRDdKampKNnhkNnNCMnlDYXQ0Z1dYX2xnRlNDRDhRaVlJcGNHaHI4ampyVTNHbmQ0ZWln?oc=5","date":"2019-07-24","type":"pipeline","source":"NEJM","summary":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis - NEJM","headline":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1paUFicFlRRndod21BSDRvV2hHaFJfNXB5SU9maHZwQUNnc19uT1JjMmZtZzRSdGl2bjcxa29uS3lZT0NOZWFfWnV4U2x4RnMtX2o2RmdzcHRrUmtpVzZodg?oc=5","date":"2019-07-24","type":"pipeline","source":"NEJM","summary":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis - NEJM","headline":"Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"discontinued":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}